Astellas Pharma Inc. Security Rating

Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. Its focus areas include urology, immunology, cardiology, infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system. The company develops XTANDI, an androgen receptor signaling inhibitor indicated for the treatment of forms of advanced prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation-positive; PADCEV, a treatment for adult patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/L1, and platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for the treatment of overactive bladder (OAB); Evrenzo, an oral treatment for anemia associated with chronic kidney disease (CKD), and Prograf and Advagraf/Graceptor/ASTAGRAF, immunosuppressants used to suppress organ rejection following a transplant.